Pubertal Growth and Final Height in Hypopituitary Boys: A Minor Role of Bone Age at Onset of Puberty*

JEAN-PIERRE BOURGUIGNON, MARK VANDEWEGHE, MAGDA VANDERSCHUEREN-LODEWEYCKX, PAUL MALVAUX, RENÉE WOLTER, MARC DU CAJU, AND CHRISTIAN ERNOULD

Belgian Study Group for Pediatric Endocrinology, Departments of Pediatrics, Universities of Liège (J.-P.B., C.E.), Louven (M.V.-L.), Louwain (P.M.), Brussels (R.W.), and Antwerp (M.D.C.); and the Department of Endocrinology, University of Ghent (M.V.), Belgium

ABSTRACT. Twenty-two hypopituitary boys treated with human GH were studied longitudinally before and during puberty. Eight patients entered spontaneous puberty at a mean bone age of 12.4 ± 1.0 (±sd) yr. Height velocity reached a mean peak of 6.8 cm/yr during the second year of spontaneous puberty. In these patients, the mean total height gain throughout puberty was 22.8 ± 5.2 cm, and the mean final height was 158.6 ± 7.2 cm. Fourteen patients received testosterone enanthate (100 mg/month, im) starting at a mean bone age of 13.6 ± 1.1 yr. Height velocity was maximal (7.5 cm/yr) during the first year of therapy. The mean final height was 162.9 ± 5.0 cm, with a mean pubertal gain of 15.9 ± 3.8 cm. Genital development, peak height velocity, and increase in plasma testosterone levels occurred earlier during testosterone therapy than during spontaneous puberty. In both groups of patients, there was a positive correlation between the bone age at onset of puberty and the age at onset of puberty (r = 0.65). There was also a negative correlation between bone age and total pubertal height gain (r = −0.73). This reduction in pubertal height increase was less than expected for bone age at onset of puberty, which can be explained by a decrease in bone age velocity in relation to bone age at onset of puberty (r = −0.81). Therefore, advancement in bone age at the onset of testosterone therapy did not impair final height, whereas it may increase height at onset of puberty, which is the major factor in final height.

We conclude that in GH- and gonadotropin-deficient boys 1) a reduced dosage of testosterone enanthate (25 mg twice a month, im) should be used to induce pubertal development, and 2) the major criterion to decide when to give testosterone is height reached at that time regardless of bone age. (J Clin Endocrinol Metab 63: 376, 1986)

MOST hypopituitary patients have multiple hormone deficiencies, including GH and gonadotropin deficiencies. In males, treatment with both androgens and human GH (hGH) is required to induce a pubertal growth spurt (3–8). Although some patients may reach a satisfactory final height, the optimal dosage of testosterone and the best age to begin androgen therapy are not known. The available data suggest that during androgen therapy, the growth spurt may depend on the age at which treatment was begun (9–14). However, no systematic study on this issue has been reported. The aim of this study was to analyze height velocity and final stature in hypopituitary patients in relation to bone age at onset of puberty and to evaluate the effects of testosterone treatment compared with the course of spontaneous puberty in hypopituitary boys.

Received October 22, 1985.
Address requests for reprints: Dr. J. P. Bourguignon, Pediatric Clinic, Hôpital de Bavière, B 4020 Liège, Belgium.
* Parts of this work (1, 2) were presented at the Seventh International Congress of Endocrinology, Quebec, Canada, July 1984, and at the Second Joint Meeting of Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology, Baltimore, MD, June 1985.

Subjects and Methods

Patients

Twenty-two hypopituitary boys were studied longitudinally. At the time of diagnosis, all had a height velocity below the third percentile according to Tanner (15). The criteria to diagnose GH deficiency and the management of the other pituitary hormone deficiencies were described previously (16). The patients were divided into two groups: boys with spontaneous puberty (n = 8) and boys with gonadotropin deficiency (n = 14). In the latter group, pubertal development was induced by giving testosterone enanthate (Testosteron depot, Schering, Bloomfield, NJ; 100 mg/month, im). The biological features of gonadotropin deficiency and the criteria used to start testosterone administration also were reported previously (16). Briefly, the criteria were 1) the absence of any sign of puberty and a decrease in height velocity (despite hGH treatment) when bone age was 11.5 yr or greater, 2) a serum LH response to GnRH (25 µg/m²) that was low for bone age, and 3) request by the patient.

All patients were treated with hGH (Crescormon, Kabi, Stockholm, Sweden) throughout the study period. hGH was given at an evening im injection of 6 IU, three times weekly. This dosage was not changed during testosterone therapy,
whereas it was increased up to 8 IU/injection at the time when signs of spontaneous puberty were observed. The mean chronological age at the beginning of hGH therapy was not significantly different between boys with gonadotropin deficiency [14.3 ± 3.6 (±SD) yr] and those who entered spontaneous puberty (12.7 ± 2.8 yr).

When puberty occurred during the first year of hGH therapy, the data were not included in the study to exclude possible catch-up of height velocity due to hGH itself (7, 12, 17-20). Treatment with hGH was stopped when height velocity declined to less than 2 cm for the previous 6 months. Patients with incomplete spontaneous puberty were excluded from this study.

Informed consent was obtained from all patients and from their parents. This investigation was completed before Creutzfeldt-Jacob disease was reported to occur in some patients previously treated with hGH (21). Since that time, the use of extractive pituitary GH has been stopped in Belgium.

Methods

All patients were followed regularly in the pediatric departments of the different Belgian university hospitals, according to a single well-defined protocol. Every 3 months, height was measured using the Harpenden stadiometer. Genital and pubic hair development were estimated according to the five stages of Tanner (22). Testicular volume was measured using the orchidometer of Prader (23). Plasma testosterone and dehydroepiandrosterone sulfate concentrations were measured by specific RIAs. During testosterone therapy, blood samples were obtained about 2 weeks after the last injection. Adrenarche was considered to be absent when plasma levels of dehydroepiandrosterone sulfate were below 200 ng/ml in patients whose bone age was greater than 11 yr (16). The onset of spontaneous puberty was defined as the time of the last examination before a testicular volume above 3 ml was found. In gonadotropin-deficient patients, the time of onset of puberty was considered to be the first day of testosterone administration.

Bone age was measured once a year before puberty and twice a year during puberty by a single examiner according to the TW2 method of Tanner et al. (24), rating 20 bones of the hand and wrist. Height age and height gain expected for bone age were calculated with reference to the 50th percentile of height according to the method of Tanner and Whitehouse (25). Ages were expressed in years and decimal fractions thereof. The sex-corrected midparental height, also called target height, was calculated according to the procedure of Tanner et al. (26). In male patients, target height is obtained by adding 6.5 cm to the arithmetic mean of the parent’s height.

Statistical analysis

The significance of differences between the two groups of patients were calculated using Student’s t test. When correlations were studied, their significance was determined from the variance, and the regression lines were compared (27). Differences were considered to be significant at \( P < 0.05 \).

Results

Clinical features of the two groups of patients

Table 1 shows the clinical data on the patients with spontaneous and testosterone-induced puberty. All were assumed to have idiopathic hypopituitarism. Among the 8 patients with spontaneous puberty, 4 had associated TSH deficiency. All 14 patients with gonadotropin deficiency had TSH deficiency, 8 of them had ACTH deficiency, and 9 no adrenarche. The mean sex-corrected midparental height (or target height) was not significantly different in the 2 groups of patients. The mean chronological age, bone age, height age, and height were significantly higher in those patients in whom testosterone had to be given than in those entering spontaneous puberty.

Pubertal score, height velocity, and bone maturation before and during puberty

As shown in Fig. 1, spontaneous and testosterone-induced puberty resulted in similar changes. The final stages of genital score and pubic hair score were reached by an increasing number of patients, height velocity and bone maturation accelerated, and plasma testosterone levels increased. However, some differences were found between the two groups of patients. After 1 yr of pubertal development, the genital score was stage 4 or 5 in 47%

| Table 1. Relevant clinical data on 22 hypopituitary boys at the time of spontaneous or induced puberty |
|-----------------|-----------------|-----------------|
|                  | Spontaneous puberty | Testosterone-induced puberty |
| Total no. of patients | 8               | 14              |
| Pituitary deficiencies GH | 8/8             | 14/14          |
| TSH               | 8/8             | 14/14          |
| FSH-LH            | 8/8             | 14/14          |
| ACTH              | 8/8             | 8/14           |
| Absence of adrenarche | 0/8            | 9/14          |
| Mean sex-corrected midparental (target) ht (cm) | 169.2 ± 4.0 | 170.8 ± 7.5* |
| Age (yr) at onset of puberty | 15.0 ± 1.2 | 18.5 ± 1.7* |
| Chronological age | 12.4 ± 0.9 | 13.6 ± 1.1d |
| Bone age          | 10.1 ± 1.3 | 12.1 ± 1.0c |
| Ht (cm) at onset of puberty | 135.8 ± 5.6 | 146.7 ± 6.2c |

Values are the mean ± SD.
* \( P = NS \) vs. spontaneous puberty.
\( ^b \) Onset of puberty for boys with spontaneous puberty was the last 3 month visit before testicular volume greater than 3 ml was found; for boys with induced puberty onset was considered to occur at the start of testosterone enanthate treatment (100 mg/month, im).
\( ^d \) \( P < 0.001 \) vs. spontaneous puberty.
Role of bone age at onset of puberty

After spontaneous puberty, the mean final height was 158.6 ± 7.2 (±SD) cm, whereas it was 162.9 ± 5.0 cm in patients treated with testosterone. Among the 8 patients who entered puberty spontaneously, only 2 had a final stature above the third percentile of height. In contrast, 9 of 14 boys with gonadotropin deficiency had a final height above the third percentile.

In patients of both groups, final height was not significantly related to bone age at onset of puberty (Fig. 2). Height at onset of puberty was a direct function (r = 0.65) of bone age at onset of puberty, whereas total pubertal height gain decreased significantly (r = −0.73) in relation to bone age at onset of puberty. The correlations were not significantly different between patients with spontaneous puberty and those treated with testosterone. The velocity of bone maturation during puberty

Fig. 1. Mean (±SD) genital score, pubic hair development (stages 4 and 5 according to Tanner), height velocity, bone maturation, and plasma testosterone levels in relation to time before and during spontaneous or testosterone-induced puberty in hypopituitary boys. The dashed line indicates that during induced puberty, mean plasma testosterone levels were similar during the 3 yr of therapy.

of the patients treated with testosterone but in none of the patients who had spontaneous puberty. In all patients receiving testosterone, peak height velocity occurred during the first year of therapy (mean, 7.5 cm/yr). Spontaneous puberty resulted in a similar peak height velocity (mean, 6.8 cm/yr), although it occurred during the second year. Mean total height gain was 22.8 ± 5.2 (±SD) cm during spontaneous puberty and 15.9 ± 3.8 cm during testosterone-induced puberty. The variations in bone maturation closely paralleled those in height velocity. During testosterone administration, the mean plasma testosterone level achieved (2.5 ng/ml) was significantly higher (P < 0.05) than that during the first year of spontaneous puberty (1.3 ng/ml) and lower (P < 0.01) than that during the third year of spontaneous puberty (5.4 ng/ml). The mean total duration of pubertal growth was 2.7 ± 0.6 (±SD) yr during testosterone treatment and 4.2 ± 0.8 yr during spontaneous puberty.

Fig. 2. Relationships between bone age at onset of puberty in hypopituitary boys and final height, height at onset of puberty, total pubertal height gain, and velocity of bone maturation during puberty.
was calculated from the total increment in bone age during that period. In patients of both groups, a highly significant negative linear correlation \((r = -0.81)\) was found between velocity of bone maturation and bone age at onset of puberty (Fig. 2).

In Fig. 3 are illustrated the linear correlations between growth parameters and bone age at onset of testosterone therapy in gonadotropin deficient patients. These data are compared with the 50th centile of height for bone age in normal boys. According to the normal growth pattern, the progression of bone age results in an increase in height equivalent to the decrease in subsequent height gain so that a definite final height is reached. In hypopituitary boys, an increase in bone age at onset of testosterone treatment between 11 and 15 yr results in a mean increase in height at that time \((+15.3\) cm) greater than the mean reduction in subsequent height gain \((-8.9\) cm). Therefore, as shown in Fig. 3, final height in testosterone-treated patients is slightly increased in relation to bone age \((+6.5\) cm). This difference may be explained by the low velocity of bone maturation during puberty in hypopituitary patients (Fig. 2).

**Factors important for final height**

As shown in the upper panel of Fig. 4, final height was a direct function of sex-corrected midparental height, also called target height \((r = 0.57)\). Therefore, final height was analyzed as a percentage of target height to exclude the possible influence of individual genetic factors in the correlations studied. Final height was found to be positively related to height at onset of puberty \((r = 0.66)\). In contrast, final height was not significantly related to height at onset of hGH therapy, duration of hGH therapy, or total pubertal height gain (Fig. 4).

**Discussion**

Our data provide the following original information concerning pubertal growth and final height in hypopituitary boys. 1) Monthly administration of 100 mg long-acting testosterone induced earlier acceleration in genital development and height velocity than did normal puberty. 2) Final height was not significantly related to bone age at onset of puberty, since an advanced bone age correlated with both an increase in height at onset of puberty and a decrease in the magnitude of the pubertal growth spurt. 3) An advanced bone age at onset of puberty resulted in a velocity of bone maturation slower than expected and subsequent height gain greater than expected. 4) Final height did not depend on pubertal growth, but it was related to height at onset of puberty. To facilitate the discussion, data from the literature are summarized in Table 2.

**Role of androgens in growth and pubertal development**

In hypopituitary boys with associated GH and gonadotropin deficiencies, peak height velocity could not be elicited by administration of testosterone alone (3, 4). In contrast, the combined administration of hGH and androgens induces satisfactory sexual development (except testicular enlargement) and acceleration in height velocity without disproportionate increase in bone maturation (1, 2, 5, 6, 8). A still debated question is the dosage of
testosterone. Monthly injections of 250 mg long-acting testosterone or more resulted in a precocious acceleration in height velocity (3, 5, 6). More recently, most researchers (Table 2) used an initial testosterone dosage of 100 mg/month (7, 8, 19, 28), which was increased to 250 mg/month after 3–12 months (7, 11, 19, 28). From our data, using 100 mg/month, it would appear that such a low dosage was too high during the first year of therapy, as suggested by the early increase in plasma testosterone levels and the early occurrence of genital development and peak height velocity. Therefore, we suggest dosages of 50 and 100 mg/month for the first and second years of therapy, respectively. In addition, a recent study on testosterone dynamics (29) indicated that the monthly dosage should be given in divided doses every 2 weeks.

During spontaneous puberty in hypopituitary boys, the mean peak height velocity varied between 6.8 and 8.1 cm/yr (5, 8, 9, 28), in agreement with the present findings. In our study, the mean total height gains throughout spontaneous and induced puberty were 22.8 and 15.9 cm, respectively. These gains are somewhat higher than the mean height gains reported by Burns et al. (28), 17.0 and 10.4 cm, respectively, but lower than the mean height gain of 27 cm in normal adolescents (10).

### Importance of hGH dosage for growth at puberty

Several researchers emphasized the relationship between hGH dosage and growth response, particularly during the first year of hGH treatment (7, 12, 20, 30, 31). The relation is exponential; a 2-fold increase in hGH dosage results in a 1.2- to 1.4-fold increase in height velocity (30, 31). In the literature (Table 2), the mean hGH dosages varied between 12 and 24 IU/week during spontaneous puberty (5, 8, 9, 13, 28) and between 12 and 20 IU/week during testosterone therapy (5–9, 11, 19, 28). However, these different dosages did not influence the peak height velocity. In a preliminary study (8), using 12 IU hGH/week, we found a peak height velocity very similar to that in the present study where doses of 24 IU/week during spontaneous puberty and 18 IU/week during testosterone therapy were used. Together with data obtained by others, our results suggest that hGH dosage should not be increased at the time of puberty.

### Bone age in relation to pubertal growth and final height

The importance of the technique used to estimate bone age should be emphasized. In the literature (Table 2), most researchers used the method of Tanner et al. TW_{50} (24) because of its great accuracy. Since the occurrence of normal puberty is more closely linked to bone age than to chronological age, evaluation of bone age is critical for deciding when to give androgen therapy. In accordance with several researchers (5, 8, 13, 19, 28), we found that spontaneous puberty occurred at a mean bone age of about 12.5 yr, whereas testosterone therapy began at a mean bone age of about 13.5 yr. However, in both groups of patients, the differences in bone age at onset of puberty did not significantly affect final height. This confirms the findings of Burns et al. (28) in hypopituitary boys. It appears that advancement in bone age at onset of puberty is associated with increased height at onset of puberty, but it reduces pubertal growth. However, when bone age at onset of puberty increased from 11 to 15 yr, the subsequent pubertal height gain was reduced much less than expected for bone age. Thus, advancement in bone age at onset of puberty is favorable to final height rather than prejudicial, as could be expected according to normal growth standards. Variations in velocity of bone maturation might account for those differences. Very little has been published on the velocity of bone age during puberty in hypopituitary patients. Milner and associates (17) found that bone maturation increased
about 1 yr for every 1 yr of chronological age regardless of bone age reached. However, these patients were not studied in relation to their pubertal development. During testosterone therapy in boys with cranio-pharyngioma, Burns et al. (10) reported a mean increase in bone age of 3.1 yr during a mean period of 2.4 yr. We found, however, that the progression of bone age was related to bone age reached at onset of puberty. In fact, when puberty began at an early bone age, bone age velocity was faster than expected. In contrast, bone age velocity was slower than expected when puberty started at a late bone age. In the former situation, the pubertal growth spurt can be somewhat impaired, whereas in the latter condition, it is greater than expected for bone age at onset of puberty.

In summary, we conclude that in GH-deficient boys, the final height attained increases in relation to height at onset of puberty regardless of bone age at the time of puberty. Although administration of testosterone at an advanced bone age results in a slight reduction in pubertal height gain, there is also a marked decrease in bone age velocity, such that the final height is improved rather than impaired. According to these observations, we recommend the following management of GH- and gonadotropin-deficient boys. 1) Begin testosterone therapy when the optimal prepubertal height is reached regardless of bone age. In small boys whose increase in height velocity during GH is sustained, testosterone therapy can be delayed beyond a bone age of 14 yr if psychologically acceptable. Such a delay will not markedly impair pubertal growth and may improve height at onset of puberty and, thus, final height. 2) A reduced dosage of testosterone enanthate, such as 25 mg every 2 weeks during the first year and 50 mg every 2 weeks during the second year, should be used to induce pubertal development.

### Acknowledgments

We are grateful to Prof. R. Eckels, president of the National Committee for Treatment of GH Deficiency, for his stimulatory comments and criticism. We appreciated helpful discussions from Drs. G.
References


12. Frasier SD 1983 Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 4:155

13. Tanner JM, Whitehouse RH 1975 A note on the bone age at which patients with true isolated growth hormone deficiency enter puberty. J Clin Endocrinol Metab 41:788


